Management of HIV-infected children in Europe

Acta Paediatrica, International Journal of Paediatrics

Volumn 92, Issue 2, 2003, Pages 139-140

  Van De Perre, Philippe ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

CHILD CARE; CLINICAL PRACTICE; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; EUROPE; GENOTYPE; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; NOTE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0037238140     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2003.tb00516.x     Document Type: Note

References (14)

1. Thorne C, Gray L, Newell M-L. Management of vertically HIV-infected children in Europe. Acta Pædiatr 2003; 92: 246-50
2. Luzuriaga K, McManus M, Catalina M, Mayak S, Sharkey M, Stevenson M, Sullivan JL. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific responses. J Virol 2000; 74: 6984-91
3. Faye A, Bertone C, Teglas JP, Chaix ML, Douard D, Firtion G, et al. Early multitherapy including a protease inhibitor for HIV infected infants. Pediatr Infect Dis 2002; 21: 518-25
4. Van Rossum AM, Niesters HG, Geelen SP, Scherpbier HJ, Hartwig NG, Weemaes CM, et al., on behalf of the Dutch Study Group for Children with HIV-1 infections. Clinical and virological response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. J Pediatr 2000; 136: 780-85.
5. Van Rossum AM, Geelen SP, Hartwig NG, Wolfs TF, Weemaes CM, Scherpbier HJ, et al. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002; 34: 1008-16
6. Nikoli-Djokic D, Essajee S, Rigaud M, Kaul A, Chandwani S, Hoover W, et al. Immune reconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. J Infect Dis 2002; 185: 290-8
7. Van Rossum AM, Fraaij PL, De Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002; 2: 93-102
8. Burger DM, Van Rossum AM, Hugen PW, Suur MH, Hartwig NG, Geelen SP, et al. Pharmacokinetics of protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 2001; 45: 701-5
9. Capparelli EV, Sullivan JL, Mofenson L, Smith E, Graham B, Britto P, et al. Pharmacokinetics of nelfinavir in human immunodeficiency virus - infected infants. Pediatr Infect Dis 2001; 20: 746-51
10. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14: 2123-8
11. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999; 18: 682-9
12. Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM and the PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. HIV Med 2002; 3: 215-26
13. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection, January 7, 2000. HIV Clin Trials 2000; 1: 53-99
14. Prise en charge des personnes infectées par le VIH. Recommandation d'un groupe d'experts. Rapport 2002 sous la direction du Professeur JF Delfraissy. Paris, France: Médecine-Science, Flammarion Edt